Development of an Automated Chemiluminescent Enzyme Immunoassay for Measuring Thrombopoietin in Human Plasma

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Feb 25

PMID 35204403

Authors

Yukihiro Nishikawa

Shiyo Nishida

Keiko Kuroda

Hirokazu Kashiwagi

Yoshiaki Tomiyama

Masataka Kuwana

Affiliations

Soon will be listed here.

Abstract

Plasma thrombopoietin (TPO) measurements help distinguish between different types of thrombocytopenia but are not feasible in routine clinical practice. We developed a fully automated quantitative chemiluminescent enzyme immunoassay (CLEIA) for measuring TPO (TPO-CLEIA), which is a one-step sandwich-type assay. This assay utilizes a mouse monoclonal capture antibody, which has the neutralizing epitope of the interaction between TPO and the TPO receptor, and a newly generated rabbit monoclonal detector antibody. In analytical performance studies, this assay showed good linearity over the measuring range and high sensitivity. The limit of quantification (LoQ) of this assay was 3.4 pg/mL; low TPO concentration values of almost all healthy individuals exceeded the LoQ value. In clinical validation studies, TPO levels obtained from patients with aplastic anemia (AA) significantly increased, whereas those of patients with immune thrombocytopenia (ITP) were normal or slightly increased. The cutoff value for TPO-CLEIA corresponding to the previously reported values was useful for distinguishing between ITP and AA. These results suggest that TPO-CLEIA can quantify human plasma TPO levels with high accuracy and sensitivity and has the potential to facilitate routine clinical measurement of TPO in patients with various types of thrombocytopenia.

References

Satoh T, Miyazaki K, Shimohira A, Amano N, Okazaki Y, Nishimoto T . Fcγ receptor IIB gene polymorphism in adult Japanese patients with primary immune thrombocytopenia. Blood. 2013; 122(11):1991-2. DOI: 10.1182/blood-2013-05-501858. View

Ishikawa E, Imagawa M, Hashida S, Yoshitake S, Hamaguchi Y, Ueno T . Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining. J Immunoassay. 1983; 4(3):209-327. DOI: 10.1080/15321818308057011. View

Saito C, Ishiyama K, Yamazaki H, Zaimoku Y, Nakao S . Hypomegakaryocytic thrombocytopenia (HMT): an immune-mediated bone marrow failure characterized by an increased number of PNH-phenotype cells and high plasma thrombopoietin levels. Br J Haematol. 2016; 175(2):246-251. DOI: 10.1111/bjh.14210. View

Kato T, Matsumoto A, Ogami K, Tahara T, Morita H, Miyazaki H . Native thrombopoietin: structure and function. Stem Cells. 1998; 16(5):322-8. DOI: 10.1002/stem.160322. View

Tahara T, Kuwaki T, Matsumoto A, Morita H, Watarai H, Inagaki Y . Neutralization of biological activity and inhibition of receptor binding by antibodies against human thrombopoietin. Stem Cells. 1998; 16(1):54-60. DOI: 10.1002/stem.160054. View

Seiki Y, Sasaki Y, Hosokawa K, Saito C, Sugimori N, Yamazaki H . Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure. Haematologica. 2013; 98(6):901-7. PMC: 3669446. DOI: 10.3324/haematol.2012.066217. View

Panteghini M, Forest J . Standardization in laboratory medicine: new challenges. Clin Chim Acta. 2005; 355(1-2):1-12. DOI: 10.1016/j.cccn.2004.12.003. View

Cinquanta L, Fontana D, Bizzaro N . Chemiluminescent immunoassay technology: what does it change in autoantibody detection?. Auto Immun Highlights. 2017; 8(1):9. PMC: 5483212. DOI: 10.1007/s13317-017-0097-2. View

Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M . cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994; 369(6481):571-4. DOI: 10.1038/369571a0. View

10.

Tahara T, Usuki K, Sato H, Ohashi H, Morita H, Tsumura H . A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol. 1996; 93(4):783-8. DOI: 10.1046/j.1365-2141.1996.d01-1741.x. View

11.

Friedberg J . Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011; 2011:498-505. DOI: 10.1182/asheducation-2011.1.498. View

12.

Kashiwagi H, Tomiyama Y . Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013; 98(1):24-33. DOI: 10.1007/s12185-013-1370-4. View

13.

de Sauvage F, Luoh S, Ryan A, Dowd M, Eaton D, Moore M . Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 1996; 183(2):651-6. PMC: 2192470. DOI: 10.1084/jem.183.2.651. View

14.

Porcelijn L, Folman C, Bossers B, Huiskes E, Overbeeke M, v d Schoot C . The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost. 1998; 79(6):1101-5. View

15.

Aledort L, Hayward C, Chen M, Nichol J, Bussel J . Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004; 76(3):205-13. DOI: 10.1002/ajh.20104. View

16.

Neunert C, Terrell D, Arnold D, Buchanan G, Cines D, Cooper N . American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3(23):3829-3866. PMC: 6963252. DOI: 10.1182/bloodadvances.2019000966. View

17.

Kuwana M, Kurata Y, Fujimura K, Fujisawa K, Wada H, Nagasawa T . Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by multi-center prospective study. J Thromb Haemost. 2006; 4(9):1936-43. DOI: 10.1111/j.1538-7836.2006.02091.x. View

18.

Marini I, Zlamal J, Faul C, Holzer U, Hammer S, Pelzl L . Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan. Haematologica. 2019; 106(1):196-207. PMC: 7776251. DOI: 10.3324/haematol.2019.236117. View

19.

McMillan R . The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2008; 44(4 Suppl 5):S3-S11. DOI: 10.1053/j.seminhematol.2007.11.002. View

20.

Panteghini M . Traceability as a unique tool to improve standardization in laboratory medicine. Clin Biochem. 2009; 42(4-5):236-40. DOI: 10.1016/j.clinbiochem.2008.09.098. View